GlobeNewswire by notified

Copenhagen Capital A/S – Periodemeddelelse for 1. kvartal 2023

Del

Copenhagen Capital A/S afgiver periodemeddelelse for 1. kvartal 2023. Selskabet offentliggør ikke finansiel information som en del af periodemeddelelser.  

Driften af ejendommene forløber som forventet. Selskabet har i perioden overtaget ejendommene beliggende Stadionvej 92-94, 2600 Glostrup pr. 1. januar 2023 og ejendommene beliggende Rådmandsgade 43-45, 2200 København N pr. 1. marts 2023. 

Byggeprojektet på Ingemannsvej 3, 1964 Frederiksberg C og konverteringen af 2. og 3. sal på fra erhverv til bolig på Niels Hemmingsens Gade 4, 1153 København K går begge som planlagt og forventes afsluttet i Q3 2023. 

Selskabet har i januar 2023 udstedt 12.500.000 stk. 40% præferenceaktier 2032 til kurs 8,32 svarende til en samlet kursværdi på kr. 104 mio. Aktierne er blevet optaget til handel og officiel notering på Nasdaq Copenhagen. 

Selskabet har i perioden tilbagekøbt i alt 41.315.209 stk. 8% præferenceaktier 2024. Aktierne blev vedtaget annulleret på den ordinære generalforsamling. 

Copenhagen Capital A/S fastholder forventningerne til 2023 om et resultat af primær drift mellem 17,0 mio. og kr. 20,0 mio. kr. før værdireguleringer af selskabets ejendomme, regulering af gæld til markedsværdi og skat. Resultatet kan påvirkes af køb/salg af ejendomme og af renteudviklingen. 

”Vi har i første kvartal haft fokus på at sikre en langsigtet kapitalstruktur, så vi står stærkt i en tid med øget usikkerhed, høj inflation og et forandret rentemiljø. Ejendomsværdierne er under pres i et marked med lav likviditet.” udtaler direktør Rasmus Greis og fortsætter ”Vores portefølje er i god drift med forsat lav tomgang og meget få restancer.”

Med venlig hilsen

Copenhagen Capital A/S
Direktør Rasmus Greis
Telefon: +45 70271060
Email: rg@copenhagencapital.dk

Vedhæftet fil

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Mandatory Notification of Trade30.5.2023 15:43:14 CEST | Press release

Please refer to the attached forms of notification of transaction by primary insiders under the DNO ASA Employee Synthetic Share Program. This notification has been submitted pursuant to the Norwegian Securities Trading Act § 5-12 and MAR Article 19 no. 3. Attachments Form of Notification Cash Settlement Geir Arne Skau 26 05 2023Form of Notification Cash Settlement Haakon Sandborg 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Chris Spencer 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Geir Arne Skau 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Haakon Sandborg 26 05 2023Form of Notification Cash Settlement Chris Spencer 26 05 2023

Correction: Avance Gas Holding Ltd: Key information relating to the dividend for the first quarter 202330.5.2023 15:30:30 CEST | Press release

Bermuda, May 30 2023 Please note that the record date has been included to the below key information relating to dividend for the first quarter 2023. Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the first quarter 2023: Dividend amount: $0.50 Declared currency: USD Last day including right: June 6, 2023 Ex-date: June 7, 2023 Record date: June 8, 2023 Payment date: June 14, 2023 Date of Approval: May 29, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control30.5.2023 15:30:00 CEST | Press release

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the Board Proposal to remove Peter Allen, Michael Baldock, and Sally Crawford as Directors of the Company ExecutiveChairman Milner intends torestore Abcam to the valuation it deserves CAMBRIDGE, England, 30May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.3% of the Company, announced today that he has formally requisitioned the Board of Directors to convene an extraordinary general meeting of shareholders (“EGM”) to reverse a period of sustained financial and operational underperformance by providing more effective Board level leadership for the Company. The EGM will enable shareholders to vote on the following proposals: The removal of Peter Allen, Michael Baldock, and Sally Crawford from office as Directors of the

PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME30.5.2023 15:25:24 CEST | Press release

Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND, UK, ICELAND, AND MIDDLE EAST & NORTH AFRICA (MENA) TERRITORIESTHERE ARE NO CURRENT APPROVED TREATMENTS FOR BARTH SYNDROMETHIRD NEW CHEMICAL ENTITY DEAL FOR PHARMANOVIA, EXPANDING PORTFOLIO IN CARDIOLOGY AND RARE DISEASES Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its cardiology portfolio through a new licensing agreement with US-based biopharmaceutical company, Stealth BioTherapeutics Inc. The agreement gives Pharmanovia the licensing rights to elamipretide for Barth syndrome in Europe and MENA. This is a significant milestone as ongoing studies indicate that elamipretide has the potential to improve the quality of life for people with Barth syndrom

Golar releases its 2022 Environmental, Social and Governance report30.5.2023 15:23:39 CEST | Press release

Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2022 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. Our 2022 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended). All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negat